Findings Suggest New Model for Developing Novel Therapeutic Approaches
JUPITER, FL, August 22, 2011 – Working closely with a team of researchers from Duke University, scientists from the Florida campus of The Scripps Research Institute have helped identify a molecular pathway that plays a key role in stress-related damage to the genome, the entirety of an organism's hereditary information.
The new findings, published in the journal Nature on August 21, 2011, could not only explain the development of certain human disorders, they could also offer a potential model for prevention and therapy.
While the human mind and body are built to respond to stress—the well-known "fight or flight" response, which lasts only a few minutes and raises heart rate and blood glucose levels—the response itself can cause significant damage if maintained over long periods of time.
When stress becomes chronic, this natural response can lead to a number of disease-related symptoms including peptic ulcers and cardiovascular disorders. To make matters worse, evidence indicates that chronic stress eventually leads to DNA damage, which in turn can result in various neuropsychiatric conditions, miscarriages, cancer, and even aging itself.
Until the new study, however, exactly how chronic stress wreaks havoc on DNA was basically unknown.
"Precisely how chronic stress leads to DNA damage is not fully understood," said Derek Duckett, associate scientific director of the Translational Research Institute at Scripps Florida. "Our research now outlines a novel mechanism highlighting β-arrestin-1 as an important player."
The long-term effects of these stress hormones on DNA damage identified in the study represent a conceptual as well as a tangible advance, according to Robert J. Lefkowitz, a Duke University professor of medicine who led the study.
Since stress is not time-limited and can be sustained over months or even years, it is well appreciated that persistent stress may have adverse effects for the individual. These new findings not only uncover a novel pathway, but also have important practical implications.
"Our results provide a possible mechanistic basis for several recent reports suggesting that significant risk reductions for diseases such as prostate cancer, lung adenocarcinoma, and Alzheimer's disease may be associated with blockade of this particular stress-response pathway by beta blockers," Leftkowitz said. "Although there are most likely numerous pathways involved in the onset of stress-related diseases, our results raise the possibility that such therapies might reduce some of the deleterious DNA-damaging consequences of long-term stress in humans."
A Newly Discovered Mechanism
The newly uncovered mechanism involves β-arrestin-1proteins, β2-adrenoreceptors (β2ARs), and the catecholamines, the classic fight-or-flight hormones released during times of stress—adrenaline, noradrenaline, and dopamine. Arrestin proteins are involved in modifying the cell's response to neurotransmitters, hormones, and sensory signals; adrenoceptors respond to the catecholamines noradrenaline and adrenaline.
Under stress, the hormone adrenaline stimulates β2ARs expressed throughout the body, including sex cells and embryos. Through a series of complex chemical reactions, the activated receptors recruit β-arrestin-1, creating a signaling pathway that leads to catecholamine-induced degradation of the tumor suppressor protein p53, sometimes described as "the guardian of the genome."
The new findings also suggest that this degradation of p53 leads to chromosome rearrangement and a build-up of DNA damage both in normal and sex cells. These types of abnormalities are the primary cause of miscarriages, congenital defects, and mental retardation, the study noted.
The first author of the study, "Stress Response Pathway Regulates DNA Damage through β2-Adrenoreceptors and β-Arrestin-1," is Makoto R. Hara of Duke University. In addition to Duckett and Hara, other authors include Jeffrey J. Kovacs, Erin J. Whalen, Sudarshan Rajagopal, Ryan T. Strachan, Aaron J. Towers, Barbara Williams, Christopher M. Lam, Kunhong Xiao, Sudha K. Shenoy, Simon G. Gregory, Seungkirl Ahn, and Robert J. Lefkowitz of Duke University; and Wayne Grant of Scripps Research.
The study was supported by the National Institutes of Health.
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academy of Science, Engineering or Medicine—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
# # #